Illumina

Director, Global Market Access Strategy – Genetic Disease & Reproductive Health (Remote)

United States

Not SpecifiedCompensation
Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Genomics, Healthcare, Biotechnology, DiagnosticsIndustries

Requirements

Candidates must possess a Bachelor's degree, with an advanced degree being preferred. A strong background in diagnostic testing for genetic diseases and reproductive health is essential, along with deep expertise in developing and executing global market access strategies for molecular diagnostics. Experience in navigating diverse healthcare systems, payer requirements, and Health Technology Assessment (HTA) processes is necessary. Proven ability to collaborate across regional and functional teams, including Government Affairs, Commercial, Medical Affairs, and Marketing, is also required.

Responsibilities

The Director of Global Market Access Strategy will develop and lead global market access strategies for genetic disease and reproductive health diagnostic solutions. This role involves securing reimbursement and access in key markets by addressing diverse payer requirements and HTA processes, and participating in industry groups to advance testing access. Responsibilities include collaborating with cross-functional teams to shape value narratives, generating and communicating the clinical and economic value of diagnostics, and supporting evidence generation strategies. The Director will also monitor global policy trends, develop value dossiers and payer engagement materials, build relationships with external stakeholders, and provide strategic input into product development, launch planning, and lifecycle management. Additionally, the role involves leading product coding and pricing strategies and ensuring compliance with all relevant standards.

Skills

Global Market Access Strategy
Genetic Disease
Reproductive Health
Diagnostic Solutions
Molecular Diagnostics
Rare Disease
NIPT
Reimbursement
Health Technology Assessment
Value Narrative
Payer Requirements

Illumina

Supports genomics startups through funding and resources

About Illumina

Illumina focuses on fostering innovation in the genomics industry by supporting startups through its Illumina Accelerator program. This program helps entrepreneurs create, launch, and grow genomics-focused companies by providing funding and resources. The accelerator operates in two main locations: the San Francisco Bay Area and Cambridge, UK. Illumina Accelerator has successfully invested in 68 genomics startups, which have collectively raised over $1 billion in venture capital. What sets Illumina apart from its competitors is its strong partnership with leading venture capital investors and its dedicated focus on the genomics sector. The goal of Illumina is to build a thriving ecosystem for genomics innovation, enabling new companies to emerge and advance the field.

San Diego, CaliforniaHeadquarters
1998Year Founded
$27.2MTotal Funding
IPOCompany Stage
Venture Capital, BiotechnologyIndustries
5,001-10,000Employees

Risks

Over-reliance on NVIDIA's AI technology may limit flexibility in AI solution adoption.
Standardizing proteomics data across platforms could challenge Illumina's data reliability.
Single-flow-cell NovaSeq X System might cannibalize sales of higher-end models.

Differentiation

Illumina leads in genomic sequencing with advanced AI integration and multiomic data analysis.
The company offers innovative array-based solutions for DNA, RNA, and protein analysis.
Illumina's global expansion includes a new Global Capability Center in Bengaluru.

Upsides

Collaboration with NVIDIA enhances drug discovery and clinical development through AI integration.
Pilot proteomics program with UK Biobank aims to generate crucial reference datasets.
Single-cell sequencing kits make high-throughput sequencing accessible to smaller labs.

Land your dream remote job 3x faster with AI